National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Semaglutide (Ozempic®)

Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

  • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • in addition to other medicinal products for the treatment of diabetes


NCPE Assessment Process Complete
Rapid review commissioned 12/03/2018
Rapid review completed 10/04/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.


The HSE has approved reimbursement; September 2018